NCT04926285View on ClinicalTrials.gov

Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 21, 2022

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions
Relapsed or Refractory Hematologic Malignancies
Interventions
DRUG

Omacetaxine

Escalating doses of Omacetaxine 0.625 mg/m2 q12h, 1.25 mg/m2 q12h, 2.0 mg/m2 q12h, and 2.5 mg/m2 q12h

DRUG

Venetoclax

Venetoclax at 400mg

Trial Locations (1)

60612

University of Illinois Cancer Center, Chicago

All Listed Sponsors
lead

University of Illinois at Chicago

OTHER